<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neonatal polycythemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neonatal polycythemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neonatal polycythemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph A Garcia-Prats, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah O'Brien, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H30680530"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neonatal polycythemia is characterized by a venous hematocrit (HCT) that greatly exceeds normal values for gestational and postnatal age. This condition affects approximately 1 to 5 percent of newborns. Although many affected infants are asymptomatic, the characteristic clinical features are thought to result from hyperviscosity and/or the metabolic effects of an increased red blood cell mass.</p><p class="headingAnchor" id="H1"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H25989135"><span class="h2">Polycythemia</span><span class="headingEndMark"> — </span>Polycythemia is defined as hematocrit (HCT) or hemoglobin (HGB) level above the upper limit of normal (&gt;2 standard deviations) for gestational and postnatal age [<a href="#rid1">1</a>].</p><p>In term newborns, the upper limits for HCT and HGB values differ depending upon the type of blood sample:</p><p class="bulletIndent1"><span class="glyph">●</span>For <strong>peripheral venous</strong> blood samples, the upper limit for HCT is 65 percent and for HGB is 22 g/dL [<a href="#rid2">2-5</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>For <strong>capillary</strong> blood samples, the upper limit for HCT is 75 percent and for HGB is 23.7 g/dL [<a href="#rid6">6</a>]</p><p></p><p>There is considerable variability in measurements obtained from capillary samples. HCT of blood from venous samples may be as much as 15 percent lower than those obtained from capillary samples. (See <a class="local">'Laboratory testing'</a> below.)</p><p>For this reason, the diagnosis of polycythemia is based upon peripheral venous samples. A term newborn infant is considered to be polycythemic if the HCT from a peripheral venous sample is &gt;65 percent or the HGB is &gt;22 g/dL [<a href="#rid2">2-5</a>]. By convention, the definition typically is based upon the HCT rather than HGB. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h2">Hyperviscosity</span><span class="headingEndMark"> — </span>Polycythemia must be distinguished from hyperviscosity, which is defined as a blood viscosity &gt;12 centipoise, measured at a shear rate of 11.5 per second; or &gt;6 centipoise, measured at a shear rate of 106 per second [<a href="#rid7">7</a>]. A minority of infants with polycythemia have measurable hyperviscosity [<a href="#rid8">8</a>]. Conversely, some infants with hyperviscosity are not polycythemic. However, measurement of viscosity is not widely available in many clinical settings and thus clinical decisions are based on HCT.</p><p class="headingAnchor" id="H3"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>Polycythemia occurs in 1 to 2 percent of healthy newborns born at sea level and up to 5 percent of infants born at high altitude [<a href="#rid3">3,4,6,9,10</a>]. The incidence of polycythemia is influenced by the practice of delayed cord clamping since the amount of placental transfusion is increased when cord clamping is delayed [<a href="#rid11">11</a>]. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/134954.html" rel="external">"Labor and delivery: Management of the normal third stage after vaginal birth", section on 'Early versus delayed cord clamping'</a>.)</p><p>The incidence of hyperviscosity is considerably less than that of polycythemia. In studies that detected polycythemia by routine capillary screening, only 3 to 5 percent of polycythemic infants had abnormal viscosity [<a href="#rid4">4,12,13</a>]. In a separate study that used cord blood samples, hyperviscosity was detected in approximately one-half of infants with polycythemia [<a href="#rid14">14</a>]. No matter how one measures it, neonatal hyperviscosity is a fairly uncommon clinical entity.</p><p class="headingAnchor" id="H4"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Compared with older infants and children, term newborns have an increased red cell mass caused by the fetal response of increased hemoglobin production to a relatively hypoxic intrauterine environment and possibly vasomotor instability and venous pooling in the newborn immediately after birth.</p><p>The hematocrit (HCT) increases after birth, reaching a maximum at approximately two hours of age, then decreases to levels in cord blood by 18 hours of age [<a href="#rid8">8,15,16</a>].</p><p>The increased red cell mass in newborns can significantly increase blood viscosity [<a href="#rid17">17</a>]. Whole blood viscosity can also be affected by other elements of blood, including white cells, platelets, plasma proteins, immunoglobulins, or clotting factors. Nevertheless, red cell mass is the main contributor to viscosity in newborns.</p><p>Blood viscosity and HCT have a linear relationship when the HCT is &lt;60 percent [<a href="#rid5">5,12,18</a>]. This relationship becomes exponential when the HCT exceeds 65 percent, such that a small increase in HCT is associated with a dramatic increase in viscosity. The relationship is less predictable for intermediate values [<a href="#rid5">5</a>]. In one report, for example, hyperviscosity was present in 23 percent of infants with HCTs in the range of 60 to 64 percent [<a href="#rid5">5</a>].</p><p>Even for HCT values &gt;65 percent, the relationship between HCT and hyperviscosity is somewhat inconsistent. This was examined in a study of cord blood in 2461 infants of &gt;34 weeks gestation [<a href="#rid14">14</a>]. Among infants with HCT &gt;65 percent, only approximately one-half were found to have abnormal viscosity (defined as &gt;2 standard deviations above the mean for viscosity at each week of gestation).</p><p>Hyperviscosity is thought to be the main pathologic mechanism resulting in neurologic sequelae from polycythemia [<a href="#rid19">19</a>]. At high levels of viscosity blood flow to critical organs becomes impaired, leading to poor tissue perfusion. However, studies in newborn lambs suggest that decreased cerebral blood flow in polycythemia may be due in part to a vascular response to increased arterial oxygen content related to the increased hemoglobin concentration, rather than to hyperviscosity. When polycythemia was maintained in these lambs but the oxygen delivery was reduced by infusing <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a>, brain blood flow increased to baseline values [<a href="#rid20">20</a>].</p><p>Blood flow is determined by resistance to flow, which varies directly with the viscosity of the blood. However, the size (diameter) of the blood vessel affects resistance to flow more strongly than does viscosity. Thus, an increase in viscosity will reduce blood flow only if the vessel size remains constant.</p><p class="headingAnchor" id="H5"><span class="h1">CAUSES</span><span class="headingEndMark"> — </span>The causes of polycythemia are multifactorial but are due to two major mechanisms: passive (erythrocyte transfusion) and active (increased intrauterine erythropoiesis)  (<a class="graphic graphic_table graphicRef85757" href="/z/d/graphic/85757.html" rel="external">table 1</a>) [<a href="#rid21">21</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed cord clamping</strong> – The most common cause of polycythemia in otherwise healthy term infants is the practice of delaying umbilical cord clamping, which results in increased transfer of placental blood to the infant [<a href="#rid22">22,23</a>]. The usual practice is to delay cord clamping for at least 30 to 60 seconds after birth if the newborn is vigorous. This rarely results in clinically significant polycythemia. However, if there is a longer delay (eg, &gt;2 minutes), polycythemia is more likely to occur, particularly if the baby is held at a level below the mother immediately following birth, before clamping of the cord. Polycythemia can also result from unintentionally delayed cord clamping (eg, at an unattended delivery). </p><p></p><p class="bulletIndent1">In a meta-analysis of five trials involving 1025 mother-infant pairs, polycythemia occurred more frequently in infants randomized to delayed cord clamping compared with early clamping (2.5 versus 0.7 percent); however, the findings were not statistically significant (relative risk 2.56, 95% CI 0.79-8.3) [<a href="#rid11">11</a>]. Hemoglobin levels were higher among newborns in the delayed cord clamping group than in the early clamping group at 24 to 48 hours but not at subsequent assessments. More infants in the delayed cord clamping group required phototherapy for jaundice than in the early cord clamping group. There were no apparent differences between early and late clamping in neonatal mortality or long-term neurodevelopmental outcome. Additional data on delayed versus early cord clamping are presented separately. (See  <a class="medical medical_review" href="/z/d/html/134954.html" rel="external">"Labor and delivery: Management of the normal third stage after vaginal birth", section on 'Early versus delayed cord clamping'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of passive transfusion</strong> – Other associations include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Twin-to-twin transfusion, which occurs in 10 to 15 percent of monochorionic twins (see  <a class="medical medical_review" href="/z/d/html/6789.html" rel="external">"Twin-twin transfusion syndrome: Screening, prevalence, pathophysiology, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maternal-fetal transfusion, which is uncommon [<a href="#rid24">24</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Precipitous delivery (see  <a class="medical medical_review" href="/z/d/html/4449.html" rel="external">"Precipitous birth not occurring on a labor and delivery unit"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes due to increased intrauterine erythropoiesis</strong> – Increased intrauterine erythropoiesis usually results from placental insufficiency and chronic intrauterine hypoxia [<a href="#rid10">10,13</a>]. Neonatal polycythemia due to this mechanism can be seen in the following settings  (<a class="graphic graphic_table graphicRef85757" href="/z/d/graphic/85757.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants who are small for gestational age (see  <a class="medical medical_review" href="/z/d/html/5062.html" rel="external">"Infants with fetal (intrauterine) growth restriction"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maternal preeclampsia or other hypertensive or vascular disorders (see  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6805.html" rel="external">"Gestational hypertension"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancies complicated by chronic maternal hypoxemia due to cardiac or pulmonary disorders, drugs such as <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a>, smoking, or high altitude (see  <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">"Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate"</a> and  <a class="medical medical_review" href="/z/d/html/555.html" rel="external">"Asthma in pregnancy: Clinical course and physiologic changes"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants of diabetic mothers (see  <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Post-term infants (see  <a class="medical medical_review" href="/z/d/html/4972.html" rel="external">"Postterm infant"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants who are large for gestational age, including those with Beckwith-Wiedemann syndrome (see  <a class="medical medical_review" href="/z/d/html/5059.html" rel="external">"Large for gestational age (LGA) newborn"</a> and  <a class="medical medical_review" href="/z/d/html/13555.html" rel="external">"Beckwith-Wiedemann syndrome"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other endocrine abnormalities, such as congenital adrenal hyperplasia [<a href="#rid25">25</a>], hypothyroidism [<a href="#rid26">26</a>], or hyperthyroidism [<a href="#rid27">27</a>] (see  <a class="medical medical_review" href="/z/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism"</a> and  <a class="medical medical_review" href="/z/d/html/5839.html" rel="external">"Evaluation and management of neonatal Graves disease"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chromosomal anomalies, such as trisomy 21, 18, and 13 [<a href="#rid28">28</a>] (see  <a class="medical medical_review" href="/z/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities", section on 'Trisomy 18 syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities", section on 'Trisomy 13 syndrome'</a>)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H3280970082"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Most affected newborns are asymptomatic. Among symptomatic neonates, the most common signs and symptoms are gastrointestinal symptoms (poor feeding or vomiting) and cyanosis/apnea [<a href="#rid29">29,30</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic (most common)</strong> – Most polycythemic infants have no associated signs or symptoms, other than, perhaps, plethora [<a href="#rid21">21</a>]. However, plethora is a subjective finding and may not be detected in neonates with darker skin pigmentation. In asymptomatic patients, polycythemia may be noted as an incidental finding when a complete blood cell count is obtained for other reasons. In two large prospective studies of infants with polycythemia, 74 to 90 percent of affected patients were asymptomatic [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiorespiratory findings</strong> – Cardiorespiratory signs, such as cyanosis and tachycardia, are uncommon, with reported occurrence of &lt;15 percent in prospective studies [<a href="#rid29">29,30</a>]. Respiratory symptoms, including tachypnea, develop in &lt;5 percent of patients [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal symptoms</strong> – Gastrointestinal symptoms may include abdominal distension, vomiting, and poor feeding. These symptoms occur in 15 to 20 percent of affected patients [<a href="#rid29">29-31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other findings</strong> – Other findings that have been attributed to polycythemia in retrospective studies and small case series include abnormal cry, lethargy, jitteriness, hematuria, renal vein thrombosis, priapism, gallstones, hypotonia, irritability, seizures, and persistent pulmonary hypertension [<a href="#rid3">3,8,32-34</a>].</p><p></p><p>Symptoms, when present, often begin by two hours after birth, after fluid shifts have occurred and the hematocrit (HCT) is at its peak [<a href="#rid12">12</a>]. Onset may be delayed to the second or third day of life in some infants who develop polycythemia because of excessive extracellular fluid loss. In this case, the volume depletion likely exaggerates the expression of an already increased red cell mass. Infants with no symptoms by 48 to 72 hours of age are likely to remain asymptomatic [<a href="#rid15">15,35</a>].</p><p>Symptoms associated with polycythemia are thought to be due to reduced tissue perfusion or associated metabolic abnormalities, but causality has not been established [<a href="#rid20">20</a>]. These signs and symptoms are nonspecific and can occur with many other neonatal disorders.</p><p class="headingAnchor" id="H2058655798"><span class="h2">Associated laboratory abnormalities</span></p><p class="headingAnchor" id="H11"><span class="h3">Hypoglycemia</span><span class="headingEndMark"> — </span>Hypoglycemia is a common metabolic problem in newborns with polycythemia. It occurs in 12 to 40 percent of cases [<a href="#rid3">3,29,33,36</a>]. The mechanism may involve increased glucose utilization by the increased number of circulating red cells. However, there are no data to support a causal relationship, and hypoglycemia in these infants may be related to underlying causes of polycythemia (eg, polycythemia commonly occurs in infants of diabetic mothers who are at risk for hypoglycemia due to increased insulin production). (See  <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)", section on 'Hypoglycemia'</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Hyperbilirubinemia</span><span class="headingEndMark"> — </span>At least one-third of infants with polycythemia develop hyperbilirubinemia [<a href="#rid3">3</a>], most likely due to the breakdown of an increased number of circulating red cells. This may occasionally lead to the development of gallstones [<a href="#rid21">21</a>]. The actual effect of polycythemia on hyperbilirubinemia is difficult to quantify since interventions for polycythemia, such as exchange transfusion and hydration, also mitigate the hyperbilirubinemia. These treatment effects may explain why some studies do not show an association between polycythemia and hyperbilirubinemia [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications"</a> and  <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H4356714"><span class="h2">Who to test</span><span class="headingEndMark"> — </span>The hematocrit (HCT) should be measured in infants who have signs or symptoms that may be due to polycythemia, including cyanosis, tachypnea, poor feeding, and vomiting. We do <strong>not</strong> routinely measure the HCT in term infants who are well-appearing (including those with growth restriction without other concerning findings), because asymptomatic newborns with polycythemia do not appear to benefit from treatment [<a href="#rid32">32,37</a>]. (See <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H4356738"><span class="h2">Laboratory testing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pitfalls of testing</strong> – HCT values can vary substantially depending upon the type of blood sample used, age of the neonate, and method of HCT measurement:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Type of blood sample – HCT values are highest in capillary samples, intermediate in peripheral venous samples, and lowest in samples drawn from the umbilical vein [<a href="#rid5">5</a>]. In one study of newborns with peripheral venous HCTs ≥65 percent, the mean values for capillary, peripheral venous, and umbilical venous HCTs were 75, 71, and 63 percent, respectively [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age at the time of sampling – The HCT increases after birth, reaching a maximum at approximately two hours of age, then decreases to levels in cord blood by 18 hours of age [<a href="#rid8">8,15,16</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Method of HCT measurement – Values obtained from centrifuged samples are higher than those using cell counters and correlate better with blood viscosity [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to testing</strong> – The best laboratory tool to confirm the diagnosis and determine the need for intervention is a HCT measured on a peripheral venous blood sample. However, because capillary blood samples are generally easier to obtain, the HCT is often first measured on a capillary blood sample, usually taken from a warmed heel. If the capillary HCT is ≤65 percent, no further testing is needed. If the capillary HCT is &gt;65 percent, testing should be repeated on a peripheral venous blood sample. The venous HCT usually will be 5 to 15 percent lower than the capillary HCT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirming the diagnosis</strong> – The diagnosis of polycythemia is confirmed if the venous HCT is &gt;65 percent.</p><p></p><p class="bulletIndent1">A minority of infants with polycythemia have hyperviscosity [<a href="#rid8">8</a>]. Conversely, some infants with hyperviscosity are not polycythemic. However, measurement of viscosity is not widely available and is generally not performed in the clinical setting. (See <a class="local">'Hyperviscosity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional testing</strong> – Infants with confirmed polycythemia should have blood glucose and bilirubin levels measured since hypoglycemia and hyperbilirubinemia are common complications of polycythemia. (See <a class="local">'Associated laboratory abnormalities'</a> above.)</p><p></p><p class="bulletIndent1">The frequency of subsequent blood glucose and bilirubin testing depends on the initial results. Management of hypoglycemia and hyperbilirubinemia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5053.html" rel="external">"Pathogenesis, screening, and diagnosis of neonatal hypoglycemia", section on 'Timing of glucose screening'</a> and  <a class="medical medical_review" href="/z/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"</a>.)</p><p></p><p class="bulletIndent1">In most infants with polycythemia, the underlying etiology is readily apparent based upon the history and physical examination (eg, delayed cord clamping, maternal diabetes, preeclampsia, macrosomia)  (<a class="graphic graphic_table graphicRef85757" href="/z/d/graphic/85757.html" rel="external">table 1</a>). However, if the etiology is uncertain, it may be reasonable to evaluate for an underlying endocrine abnormality (eg, congenital adrenal hyperplasia or thyroid disease), particularly if there are other concerning findings.</p><p></p><p class="headingAnchor" id="H4356762"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The symptoms associated with polycythemia (eg, cyanosis, tachycardia, tachypnea, poor feeding, vomiting) are nonspecific and can occur in many neonatal disorders. Thus, other possible causes of the symptoms should be investigated. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory disorders (eg, pneumonia). (See  <a class="medical medical_review" href="/z/d/html/4964.html" rel="external">"Overview of neonatal respiratory distress and disorders of transition"</a> and  <a class="medical medical_review" href="/z/d/html/5004.html" rel="external">"Neonatal pneumonia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular abnormalities (eg, congenital heart disease, persistent pulmonary hypertension). (See  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease"</a> and  <a class="medical medical_review" href="/z/d/html/5045.html" rel="external">"Persistent pulmonary hypertension of the newborn (PPHN): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal sepsis. (See  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic disorders (eg, intracranial hemorrhage, stroke, intracranial anomalies, or metabolic abnormalities). (See  <a class="medical medical_review" href="/z/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6157.html" rel="external">"Stroke in the newborn: Classification, manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2936.html" rel="external">"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dehydration – The possibility of dehydration can be evaluated by comparison of birth weight and current weight; loss of &gt;7 percent of birth weight during the first five days of life may suggest dehydration  (<a class="graphic graphic_table graphicRef78906" href="/z/d/graphic/78906.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/5068.html" rel="external">"Overview of the routine management of the healthy newborn infant", section on 'Weight loss'</a>.)</p><p></p><p>If the symptoms are not severe, these possibilities usually can be excluded by reviewing the maternal labor and delivery course, performing a thorough physical examination, and closely observing the infant. Infants with severe or progressive symptoms generally warrant additional evaluation, which may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Pulse oximetry and chest radiograph if there are respiratory symptoms or cyanosis, with additional testing determined by results of these tests. (See  <a class="medical medical_review" href="/z/d/html/14305.html" rel="external">"Approach to cyanosis in the newborn", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/4964.html" rel="external">"Overview of neonatal respiratory distress and disorders of transition", section on 'Diagnostic approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Detailed cardiovascular examination (including four extremity blood pressure measurement). (See  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease", section on 'Physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood culture to evaluate for neonatal sepsis. (See  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Laboratory tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic panel (eg, serum electrolytes, calcium, blood urea nitrogen, creatinine) if the clinical picture is suggestive of dehydration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuroimaging (eg, head ultrasound) if there are concerning neurologic findings (eg, seizures, extreme lethargy, focal deficits). (See  <a class="medical medical_review" href="/z/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Cranial ultrasound'</a>.)</p><p></p><p class="headingAnchor" id="H25988256"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>All polycythemic infants should be observed closely for neurologic and cardiovascular symptoms and monitored for common complications, such as hypoglycemia and hyperbilirubinemia. Interventions aimed at lowering the hematocrit (HCT) include intravenous (IV) hydration and partial exchange transfusion (PET). These interventions are generally reserved for symptomatic and/or severely polycythemic neonates.</p><p>The management approach outlined below is based largely on expert opinion. Evidence supporting the long-term benefits of PET is generally lacking. Limited observational evidence suggests that there may some short-term benefits; however, there also are known risks.</p><p class="headingAnchor" id="H25988548"><span class="h2">Treat associated abnormalities</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoglycemia</strong> – Once the clinician makes the diagnosis of polycythemia, careful monitoring of blood glucose should be undertaken; if hypoglycemia is discovered, adequate glucose supplementation should be given, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/101425.html" rel="external">"Management and outcome of neonatal hypoglycemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperbilirubinemia</strong> – Serum bilirubin should be followed and hyperbilirubinemia should be treated accordingly, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"</a>.)</p><p></p><p class="headingAnchor" id="H4157552264"><span class="h2">Approach to treating polycythemia</span></p><p class="headingAnchor" id="H25988283"><span class="h3">Asymptomatic infants</span><span class="headingEndMark"> — </span>In asymptomatic infants, polycythemia may be noted as an incidental finding when a complete blood cell count is obtained for other reasons. Management of asymptomatic infants is usually guided by the hematocrit (HCT)  (<a class="graphic graphic_algorithm graphicRef85758" href="/z/d/graphic/85758.html" rel="external">algorithm 1</a>) (in this context, plethora is not considered a symptom):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCT ≤70 percent</strong> – Infants who are asymptomatic and have a peripheral venous HCT ≤70 percent should be observed. Adequate hydration and glucose intake should be ensured by monitoring oral intake, body weight, and urine output. The venous HCT should be repeated in 12 to 24 hours, while monitoring closely for the development of symptoms. If the HCT remains ≤70 percent and the infant remains asymptomatic, supportive care is continued for 24 hours and the HCT rechecked.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCT &gt;70 percent</strong> – If the HCT is &gt;70 percent, management options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Many centers (including the author's institution) manage such infants with continued observation, with or without IV hydration (see <a class="local">'Intravenous hydration'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some centers perform PET in asymptomatic infants only if the venous HCT is &gt;75 percent [<a href="#rid39">39,40</a>] (see <a class="local">'Partial exchange transfusion'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some centers perform PET for any infant with a venous HCT &gt;70 percent, even if the infant is asymptomatic (this approach is uncommon) [<a href="#rid41">41-43</a>] (see <a class="local">'Partial exchange transfusion'</a> below)</p><p></p><p class="headingAnchor" id="H25988290"><span class="h3">Symptomatic infants</span><span class="headingEndMark"> — </span>The optimal management of polycythemic infants (ie, peripheral venous HCT &gt;65 percent) with associated signs and symptoms (cyanosis, apnea, poor feeding, vomiting, hypoglycemia) has not been established and varies among centers  (<a class="graphic graphic_algorithm graphicRef85758" href="/z/d/graphic/85758.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsevere symptoms</strong> – For infants with nonsevere symptoms, our preferred approach is to provide IV hydration and continued observation (see <a class="local">'Intravenous hydration'</a> below). Other centers may perform PET in this setting [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe symptoms</strong> – Infants with severe signs and symptoms (eg, significant cyanosis/apnea, severe gastrointestinal symptoms, severe hypoglycemia) should undergo a thorough evaluation for other causes of these symptoms, as discussed above (see <a class="local">'Differential diagnosis'</a> above). If another cause is identified, management focuses on addressing the primary cause.</p><p></p><p>If the symptoms appear to be attributable to polycythemia, we initially manage the infant with IV hydration (see <a class="local">'Intravenous hydration'</a> below). If symptoms persist or worsen despite adequate IV hydration, we proceed with PET. When the decision is made to perform PET, it should be done as soon as possible because the neonatal HCT and blood viscosity peak between two and four hours after birth [<a href="#rid41">41</a>]. (See <a class="local">'Partial exchange transfusion'</a> below.)</p><p class="headingAnchor" id="H1285163741"><span class="h2">Interventions</span></p><p class="headingAnchor" id="H2420051978"><span class="h3">Intravenous hydration</span><span class="headingEndMark"> — </span>The primary rationale for administering IV fluids in newborns with polycythemia is to prevent and treat hypoglycemia, which is a common complication of polycythemia (see <a class="local">'Hypoglycemia'</a> above). IV fluid is provided for the first 24 to 48 hours of age at a rate of at least 100 mL/kg per day, including glucose (dextrose) at a rate of 6 to 8 mg/kg per minute, while the infant is closely monitored. The goal is to maintain normal blood glucose and adequate hydration. Additional details regarding <a class="drug drug_pediatric" data-topicid="13222" href="/z/d/drug information/13222.html" rel="external">IV dextrose</a> for treatment of neonatal hypoglycemia are provided separately. (See  <a class="medical medical_review" href="/z/d/html/101425.html" rel="external">"Management and outcome of neonatal hypoglycemia", section on 'IV dextrose infusion'</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Partial exchange transfusion</span><span class="headingEndMark"> — </span>Isovolumetric PET reduces the HCT without causing hypovolemia. There is some evidence that PET has beneficial short-term effects on measures of perfusion. However, a long-term benefit of PET in infants with polycythemia has not been demonstrated. (See <a class="local">'Outcome'</a> below.)</p><p class="headingAnchor" id="H616957184"><span class="h4">Efficacy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short-term effects</strong> – In clinical studies, PET has been found to have beneficial effects on physiologic measures related to viscosity (eg, cerebral blood flow, cardiac index, oxygen transport) [<a href="#rid7">7,37,44-48</a>]; however, PET has <strong>not</strong> been demonstrated to alter the symptoms associated with polycythemia [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term effects</strong> – Based on the available evidence, PET does <strong>not</strong> appear to improve long-term outcomes. Several small clinical trials and two meta-analyses have found that long-term neurodevelopmental outcomes are similar among infants managed with and without PET [<a href="#rid29">29,30,32,33,37,49-51</a>]. In addition, the risk of gastrointestinal injury may be increased with PET [<a href="#rid50">50,51</a>]. (See <a class="local">'Complications'</a> below and <a class="local">'Outcome'</a> below.)</p><p></p><p class="bulletIndent1">In most studies evaluating PET, the intervention was usually performed after six hours of life, so the effect of earlier intervention is unknown.</p><p></p><p class="headingAnchor" id="H19"><span class="h4">Technique</span><span class="headingEndMark"> — </span>PET can be performed in several ways. The procedure is generally similar to exchange transfusion used in management of neonatal hyperbilirubinemia with two key distinctions: PET involves a smaller exchange volume, and it uses normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> for replacement rather than reconstituted blood. (See  <a class="medical medical_review" href="/z/d/html/121592.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Escalation of care", section on 'Exchange transfusion'</a>.)</p><p>PET involves removing blood from an intravascular catheter (typically an umbilical venous catheter [UVC]) and infusing normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> through a peripheral intravenous (PIV) catheter [<a href="#rid52">52,53</a>].</p><p>The usual exchange volume is 15 to 20 mL/kg. Alternatively, it can be calculated using the following formula:</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">Exchange volume (in mL) = [(observed HCT – desired HCT) × blood volume in mL] ÷ observed HCT</p></div></div><p></p><p>The desired HCT is usually set at 55 percent. Blood volume is estimated at 80 to 100 mL/kg body weight. Higher volumes may be appropriate in infants with lower gestational ages and/or those who have polycythemia due to delayed cord clamping.</p><p>For example, for a term neonate weighing 3 kg whose HCT is 75 percent, the exchange volume would be calculated as follows:</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">Exchange volume = [(75 percent – 55 percent) × (80 mL/kg × 3 kg)] ÷ 75 percent = 64 mL</p></div></div><p></p><p>Blood can be withdrawn from the UVC while simultaneously infusing <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> continuously via the PIV (isovolumetric technique). This technique is preferred in unstable infants. Alternatively, the process can be accomplished using serial aliquots of 10 mL/kg.</p><p class="headingAnchor" id="H20"><span class="h4">Complications</span><span class="headingEndMark"> — </span>The risk of necrotizing enterocolitis may be increased in infants with polycythemia who are treated with PET [<a href="#rid50">50,51</a>]. In a small clinical trial, necrotizing enterocolitis developed in 8 of 43 patients with hyperviscosity who underwent PET and in none of the controls [<a href="#rid54">54</a>]. Treated infants also had significantly more gastrointestinal symptoms (eg, abdominal distension, bloody stools, emesis). In contrast, in a retrospective analysis of 185 polycythemic term infants treated with PET, the prevalence of gastrointestinal symptoms did not appear to differ before or after the procedure (8 versus 7 percent, respectively) [<a href="#rid31">31</a>]. No patients in this study had severe gastrointestinal injury. The conflicting findings might be explained by differences between the PET techniques used in the two studies. The clinical trial used serial aliquots to perform the PET whereas the second study used an isovolumetric technique (ie, simultaneously replacing volume through a peripheral catheter as blood was withdrawn from an umbilical venous catheter). In addition, because the second study did not test and select patients for hyperviscosity, the population studied may have been at lower risk for complications. The study is also limited by its retrospective nature and lack of a control group. (See  <a class="medical medical_review" href="/z/d/html/5019.html" rel="external">"Neonatal necrotizing enterocolitis: Clinical features and diagnosis"</a>.)</p><p>In addition, there are risks attributable to placement of the UVC (eg, thrombosis). (See  <a class="medical medical_review" href="/z/d/html/6385.html" rel="external">"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies", section on 'Umbilical vein access'</a> and  <a class="medical medical_review" href="/z/d/html/5912.html" rel="external">"Neonatal thrombosis: Clinical features and diagnosis", section on 'Catheter-associated thrombosis'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Whether neonatal polycythemia or its treatment affect long-term outcome is uncertain. The available evidence suggests that the clinical outcome may depend more upon associated conditions (eg, hypoglycemia), or the underlying disorder (eg, placental insufficiency), than on polycythemia itself. As previously discussed, partial exchange transfusion (PET) has not been shown to impact long-term outcomes [<a href="#rid50">50,51</a>]. (See <a class="local">'Efficacy'</a> above.)</p><p>Studies evaluating the effects of polycythemia and hyperviscosity on long-term neurodevelopmental outcomes have produced conflicting results. Some studies have found associations between hyperviscosity and neurologic sequelae, such as motor and speech delays, intellectual disability, and lower academic achievement [<a href="#rid29">29,30,33,49</a>], while others have not found an association [<a href="#rid32">32,37</a>].</p><p>A study evaluating three-year outcomes of 111 newborns with hyperviscosity (of whom 42 received PET) compared with 110 nonpolycythemic neonates who were matched for birthweight and gestational age controls found that infants with hyperviscosity had more motor and neurologic abnormalities compared with controls (38 versus 11 percent). These findings did not differ according to treatment [<a href="#rid30">30</a>]. Maternal preeclampsia and neonatal hypoglycemia were more common in the hyperviscosity group than in the control group. In addition, many infants in both groups were lost to follow-up, including approximately one-third of the patients with hyperviscosity.</p><p>A similar study compared neurodevelopmental outcomes of 93 infants with hyperviscosity, one-half of whom were randomly assigned to receive PET, with 93 controls [<a href="#rid29">29</a>]. Hyperviscosity was associated with delays in speech and fine motor development at one and two years of age, and persistent effects on intelligence quotient (IQ) scores and academic achievement also were seen in the patients available for follow-up at seven years of age (53 percent of the original cohort) [<a href="#rid49">49</a>]. Among the infants with hyperviscosity, treatment with PET was not associated with effects on any of these neurodevelopmental outcomes, except for neurologic diagnoses and fine motor abnormalities at two years of age; no differences were noted at seven years.</p><p>By contrast, in a study of 71 infants with neonatal polycythemia identified by routine screening, of whom 46 were available for follow-up at an average age of 30 months, neurodevelopmental outcomes were similar among infants with symptomatic hyperviscosity, asymptomatic hyperviscosity, and asymptomatic infants with normal viscosity [<a href="#rid37">37</a>]. Another study reported normal neurologic and developmental achievement at eight months and at two years of age among 49 infants with polycythemia and hyperviscosity treated with and without PET [<a href="#rid32">32</a>].</p><p>There are important limitations to these studies that preclude a clear understanding of the effects of polycythemia or a firm answer on the clinical benefits of PET. Most reports include patients with polycythemia detected by routine screening who also had documented hyperviscosity. Thus, the results may not apply to infants with polycythemia alone or those in whom polycythemia was detected, because they were symptomatic. Most studies did not control for pre-existing confounders such as maternal diabetes, smoking, or intrauterine growth retardation, so the observed differences in neurodevelopmental outcomes may not be caused by the polycythemia. In studies evaluating PET, the intervention was usually performed after six hours of life, so the effect of earlier intervention is unknown.</p><p class="headingAnchor" id="H30680580"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and incidence</strong> – Neonatal polycythemia is characterized by a venous hematocrit (HCT) that greatly exceeds normal values. A term newborn infant is considered to be polycythemic if the HCT from a peripheral venous sample is &gt;65 percent or the hemoglobin is &gt;22 g/dL. The condition affects approximately 1 to 5 percent of newborns. (See <a class="local">'Definitions'</a> above and <a class="local">'Incidence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology and pathophysiology</strong> – The most common cause of polycythemia in an otherwise healthy term infant is delayed clamping of the umbilical cord. Other causes include twin-twin transfusion, placental insufficiency, maternal hypoxemia or diabetes, and infant risk factors including macrosomia and endocrine abnormalities  (<a class="graphic graphic_table graphicRef85757" href="/z/d/graphic/85757.html" rel="external">table 1</a>). Clinical manifestations of polycythemia are thought to result from hyperviscosity and/or the metabolic effects of an increased red blood cell mass. (See <a class="local">'Causes'</a> above and <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Signs and symptoms</strong> – Most infants with polycythemia are asymptomatic, other than, perhaps, plethora. Associated symptoms may include cyanosis, apnea, vomiting, or poor feeding. When present, symptoms often begin by two hours after birth but may be delayed to the second or third day in some infants. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Associated laboratory abnormalities</strong> – Hypoglycemia and hyperbilirubinemia are commonly associated with polycythemia. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Who to test</strong> – HCT should be measured in infants who have signs or symptoms that may be due to polycythemia (cyanosis, tachypnea, poor feeding, vomiting). We do <strong>not</strong> routinely measure the HCT in infants who are well-appearing (including those with growth restriction without other concerning findings). (See <a class="local">'Who to test'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Approach to testing</strong> – The HCT is often first measured on a capillary blood sample, usually taken from a warmed heel. If the capillary HCT is ≤65 percent, no further testing is needed. If the capillary HCT is &gt;65 percent, testing should be repeated on a peripheral venous blood sample. The diagnosis of polycythemia is confirmed if the venous HCT is &gt;65 percent. (See <a class="local">'Laboratory testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional testing</strong> – Infants with confirmed polycythemia should have blood glucose and bilirubin levels measured since hypoglycemia and hyperbilirubinemia are commonly associated with polycythemia. Management of hypoglycemia and hyperbilirubinemia are discussed. (See  <a class="medical medical_review" href="/z/d/html/5053.html" rel="external">"Pathogenesis, screening, and diagnosis of neonatal hypoglycemia", section on 'Timing of glucose screening'</a> and  <a class="medical medical_review" href="/z/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Signs and symptoms associated with polycythemia (eg, cyanosis, tachycardia, tachypnea, poor feeding, vomiting) are nonspecific and can occur in many neonatal disorders. Thus, other possible causes of the symptoms should be investigated, including respiratory disorders (eg, pneumonia), cardiovascular abnormalities (eg, congenital heart disease, persistent pulmonary hypertension), sepsis, neurologic disorders (eg, intracranial hemorrhage, stroke), and dehydration. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Management of neonatal polycythemia depends upon the degree of symptoms  (<a class="graphic graphic_algorithm graphicRef85758" href="/z/d/graphic/85758.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic</strong> <strong>patients</strong> – For asymptomatic newborns, we suggest supportive care alone rather than partial exchange transfusion (PET) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Supportive care consists of monitoring oral intake, body weight, and urine output to ensure adequate hydration and glucose intake. The venous HCT should be repeated in 12 to 24 hours, while monitoring closely for the development of symptoms.</p><p></p><p class="bulletIndent2">Supportive care alone is generally sufficient for asymptomatic patients. However, some centers may use PET in asymptomatic patients, particularly if the HCT is &gt;75 percent. (See <a class="local">'Asymptomatic infants'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptomatic</strong> <strong>patients</strong> – For most infants with symptomatic polycythemia, we suggest initial treatment with supportive care (including intravenous [IV] hydration with dextrose) rather than PET (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Management also includes close monitoring of urine output and evaluation for other possible reasons for the symptoms. PET is a reasonable alternative treatment based on limited data on short-term beneficial effects. However, the available evidence suggests that PET does not improve long-term neurodevelopmental outcome and PET is associated with known risks. We generally limit use of PET to patients with severe progressive symptoms despite initial management with IV hydration. (See <a class="local">'Symptomatic infants'</a> above and <a class="local">'Partial exchange transfusion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Whether neonatal polycythemia or its treatment affect long-term outcome is uncertain. The available evidence suggests that the clinical outcome may depend more upon associated conditions, such as hypoglycemia, or on the underlying disorder (eg, placental insufficiency), than on polycythemia itself. (See <a class="local">'Outcome'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Luchtman-Jones L, Wilson DB. Hematologic problems in the fetus and neonate. In: Neonatal-Perinatal Medicine, 9, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. p.1303.</li><li class="breakAll">Oski FA, Naiman JL. Polycythemia and hyperviscosity in the neonatal period. In: Hematologic Problems in the Newborn, 3 ed, Oski FA (Ed), WB Saunders, New York 1982. p.87.</li><li><a class="nounderline abstract_t">Wiswell TE, Cornish JD, Northam RS. Neonatal polycythemia: frequency of clinical manifestations and other associated findings. Pediatrics 1986; 78:26.</a></li><li><a class="nounderline abstract_t">Stevens K, Wirth FH. Incidence of neonatal hyperviscosity at sea level. J Pediatr 1980; 97:118.</a></li><li><a class="nounderline abstract_t">Ramamurthy, RS. Neonatal polycythemia and hyperviscosity; state of the art. Perinatology-Neonatology 1979; 3:38.</a></li><li class="breakAll">Gallagher PG. The neonatal erythrocyte and its disorders. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood, 8th ed, Orkin SH, Fisher DE, Look T, Lux SE, Ginsburg D, Nathan DG (Eds), WB Saunders, Philadelphia 2015. p.52.</li><li><a class="nounderline abstract_t">Swetnam SM, Yabek SM, Alverson DC. Hemodynamic consequences of neonatal polycythemia. J Pediatr 1987; 110:443.</a></li><li><a class="nounderline abstract_t">Ramamurthy RS, Brans YW. Neonatal polycythemia: I. Criteria for diagnosis and treatment. Pediatrics 1981; 68:168.</a></li><li><a class="nounderline abstract_t">Brooks GI, Backes CR. Hyperviscosity secondary to polycythemia in the appropriate for gestational age neonate. J Am Osteopath Assoc 1981; 80:415.</a></li><li><a class="nounderline abstract_t">Rawlings JS, Pettett G, Wiswell TE, Clapper J. Estimated blood volumes in polycythemic neonates as a function of birth weight. J Pediatr 1982; 101:594.</a></li><li><a class="nounderline abstract_t">McDonald SJ, Middleton P, Dowswell T, Morris PS. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Cochrane Database Syst Rev 2013; :CD004074.</a></li><li><a class="nounderline abstract_t">Gross GP, Hathaway WE, McGaughey HR. Hyperviscosity in the neonate. J Pediatr 1973; 82:1004.</a></li><li><a class="nounderline abstract_t">Wirth FH, Goldberg KE, Lubchenco LO. Neonatal hyperviscosity: I. Incidence. Pediatrics 1979; 63:833.</a></li><li><a class="nounderline abstract_t">Drew JH, Guaran RL, Grauer S, Hobbs JB. Cord whole blood hyperviscosity: measurement, definition, incidence and clinical features. J Paediatr Child Health 1991; 27:363.</a></li><li><a class="nounderline abstract_t">Shohat M, Reisner SH, Mimouni F, Merlob P. Neonatal polycythemia: II. Definition related to time of sampling. Pediatrics 1984; 73:11.</a></li><li><a class="nounderline abstract_t">Ramamurthy RS, Berlanga M. Postnatal alteration in hematocrit and viscosity in normal and polycythemic infants. J Pediatr 1987; 110:929.</a></li><li><a class="nounderline abstract_t">Lowe GD. Rheological influences on thrombosis. Baillieres Best Pract Res Clin Haematol 1999; 12:435.</a></li><li><a class="nounderline abstract_t">Christensen RD, Baer VL, Gerday E, et al. Whole-blood viscosity in the neonate: effects of gestational age, hematocrit, mean corpuscular volume and umbilical cord milking. J Perinatol 2014; 34:16.</a></li><li><a class="nounderline abstract_t">Drew JH, Guaran RL, Cichello M, Hobbs JB. Neonatal whole blood hyperviscosity: the important factor influencing later neurologic function is the viscosity and not the polycythemia. Clin Hemorheol Microcirc 1997; 17:67.</a></li><li><a class="nounderline abstract_t">Rosenkrantz TS, Stonestreet BS, Hansen NB, et al. Cerebral blood flow in the newborn lamb with polycythemia and hyperviscosity. J Pediatr 1984; 104:276.</a></li><li class="breakAll">Mentzer WC, Glader BE. Erythrocyte disorders in infancy. In: Avery's Diseases of the Newborn, 7 ed, Taeusch HW, Ballard RA (Eds), WB Saunders, Philadelphia 1998. p.1080.</li><li><a class="nounderline abstract_t">Capasso L, Raimondi F, Capasso A, et al. Early cord clamping protects at-risk neonates from polycythemia. Biol Neonate 2003; 83:197.</a></li><li><a class="nounderline abstract_t">Strauss RG, Mock DM, Johnson K, et al. Circulating RBC volume, measured with biotinylated RBCs, is superior to the Hct to document the hematologic effects of delayed versus immediate umbilical cord clamping in preterm neonates. Transfusion 2003; 43:1168.</a></li><li><a class="nounderline abstract_t">MICHAEL AF Jr, MAUER AM. Maternal-fetal transfusion as a cause of plethora in the neonatal period. Pediatrics 1961; 28:458.</a></li><li><a class="nounderline abstract_t">GOLD AP, MICHAEL AF Jr. Congenital adrenal hyperplasia associated with polycythemia. Pediatrics 1959; 23:727.</a></li><li><a class="nounderline abstract_t">Weinblatt ME, Fort P, Kochen J, DiMayio M. Polycythemia in hypothyroid infants. Am J Dis Child 1987; 141:1121.</a></li><li><a class="nounderline abstract_t">Bussmann YL, Tillman ML, Pagliara AS. Neonatal thyrotoxicosis associated with the hyperviscosity syndrome. J Pediatr 1977; 90:266.</a></li><li><a class="nounderline abstract_t">Mentzer WC. Polycythaemia and the hyperviscosity syndrome in newborn infants. Clin Haematol 1978; 7:63.</a></li><li><a class="nounderline abstract_t">Black VD, Lubchenco LO, Koops BL, et al. Neonatal hyperviscosity: randomized study of effect of partial plasma exchange transfusion on long-term outcome. Pediatrics 1985; 75:1048.</a></li><li><a class="nounderline abstract_t">Black VD, Lubchenco LO, Luckey DW, et al. Developmental and neurologic sequelae of neonatal hyperviscosity syndrome. Pediatrics 1982; 69:426.</a></li><li><a class="nounderline abstract_t">Hein HA, Lathrop SS. Partial exchange transfusion in term, polycythemic neonates: absence of association with severe gastrointestinal injury. Pediatrics 1987; 80:75.</a></li><li><a class="nounderline abstract_t">Malan AF, de V Heese H. The management of polycythaemia in the newborn infant. Early Hum Dev 1980; 4:393.</a></li><li><a class="nounderline abstract_t">Goldberg K, Wirth FH, Hathaway WE, et al. Neonatal hyperviscosity. II. Effect of partial plasma exchange transfusion. Pediatrics 1982; 69:419.</a></li><li><a class="nounderline abstract_t">Katz J, Rodriguez E, Mandani G, Branson HE. Normal coagulation findings, thrombocytopenia, and peripheral hemoconcentration in neonatal polycythemia. J Pediatr 1982; 101:99.</a></li><li class="breakAll">Phibbs RH. Neonatal polycythemia. In: Rudolph's Pediatrics, 20 ed, Rudolph AM (Ed), Appleton &amp; Lange, Stamford, CT 1996. p.252.</li><li><a class="nounderline abstract_t">Black VD, Lubchenco LO. Neonatal polycythemia and hyperviscosity. Pediatr Clin North Am 1982; 29:1137.</a></li><li><a class="nounderline abstract_t">Bada HS, Korones SB, Pourcyrous M, et al. Asymptomatic syndrome of polycythemic hyperviscosity: effect of partial plasma exchange transfusion. J Pediatr 1992; 120:579.</a></li><li><a class="nounderline abstract_t">Villalta IA, Pramanik AK, Diaz-Blanco J, Herbst JJ. Diagnostic errors in neonatal polycythemia based on method of hematocrit determination. J Pediatr 1989; 115:460.</a></li><li><a class="nounderline abstract_t">Sankar MJ, Agarwal R, Deorari A, Paul VK. Management of polycythemia in neonates. Indian J Pediatr 2010; 77:1117.</a></li><li><a class="nounderline abstract_t">Schimmel MS, Bromiker R, Soll RF. Neonatal polycythemia: is partial exchange transfusion justified? Clin Perinatol 2004; 31:545.</a></li><li><a class="nounderline abstract_t">Mimouni FB, Merlob P, Dollberg S, et al. Neonatal polycythaemia: critical review and a consensus statement of the Israeli Neonatology Association. Acta Paediatr 2011; 100:1290.</a></li><li><a class="nounderline abstract_t">Acunas B, Celtik C, Vatansever U, Karasalihoglu S. Thrombocytopenia: an important indicator for the application of partial exchange transfusion in polycythemic newborn infants? Pediatr Int 2000; 42:343.</a></li><li><a class="nounderline abstract_t">Kumar A, Ramji S. Effect of partial exchange transfusion in asymptomatic polycythemic LBW babies. Indian Pediatr 2004; 41:366.</a></li><li><a class="nounderline abstract_t">Rosenkrantz TS, Oh W. Cerebral blood flow velocity in infants with polycythemia and hyperviscosity: effects of partial exchange transfusion with Plasmanate. J Pediatr 1982; 101:94.</a></li><li><a class="nounderline abstract_t">Bada HS, Korones SB, Kolni HW, et al. Partial plasma exchange transfusion improves cerebral hemodynamics in symptomatic neonatal polycythemia. Am J Med Sci 1986; 291:157.</a></li><li><a class="nounderline abstract_t">Maertzdorf WJ, Tangelder GJ, Slaaf DW, Blanco CE. Effects of partial plasma exchange transfusion on cerebral blood flow velocity in polycythaemic preterm, term and small for date newborn infants. Eur J Pediatr 1989; 148:774.</a></li><li><a class="nounderline abstract_t">Ergenekon E, Hirfanoglu IM, Turan O, et al. Partial exchange transfusion results in increased cerebral oxygenation and faster peripheral microcirculation in newborns with polycythemia. Acta Paediatr 2011; 100:1432.</a></li><li><a class="nounderline abstract_t">Murphy DJ Jr, Reller MD, Meyer RA, Kaplan S. Effects of neonatal polycythemia and partial exchange transfusion on cardiac function: an echocardiographic study. Pediatrics 1985; 76:909.</a></li><li><a class="nounderline abstract_t">Delaney-Black V, Camp BW, Lubchenco LO, et al. Neonatal hyperviscosity association with lower achievement and IQ scores at school age. Pediatrics 1989; 83:662.</a></li><li><a class="nounderline abstract_t">Dempsey EM, Barrington K. Short and long term outcomes following partial exchange transfusion in the polycythaemic newborn: a systematic review. Arch Dis Child Fetal Neonatal Ed 2006; 91:F2.</a></li><li><a class="nounderline abstract_t">Ozek E, Soll R, Schimmel MS. Partial exchange transfusion to prevent neurodevelopmental disability in infants with polycythemia. Cochrane Database Syst Rev 2010; :CD005089.</a></li><li><a class="nounderline abstract_t">de Waal KA, Baerts W, Offringa M. Systematic review of the optimal fluid for dilutional exchange transfusion in neonatal polycythaemia. Arch Dis Child Fetal Neonatal Ed 2006; 91:F7.</a></li><li><a class="nounderline abstract_t">Dempsey EM, Barrington K. Crystalloid or colloid for partial exchange transfusion in neonatal polycythemia: a systematic review and meta-analysis. Acta Paediatr 2005; 94:1650.</a></li><li><a class="nounderline abstract_t">Black VD, Rumack CM, Lubchenco LO, Koops BL. Gastrointestinal injury in polycythemic term infants. Pediatrics 1985; 76:225.</a></li></ol></div><div id="topicVersionRevision">Topic 5940 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Luchtman-Jones L, Wilson DB. Hematologic problems in the fetus and neonate. In: Neonatal-Perinatal Medicine, 9, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. p.1303.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Oski FA, Naiman JL. Polycythemia and hyperviscosity in the neonatal period. In: Hematologic Problems in the Newborn, 3 ed, Oski FA (Ed), WB Saunders, New York 1982. p.87.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3725498" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neonatal polycythemia: frequency of clinical manifestations and other associated findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7381630" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of neonatal hyperviscosity at sea level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neonatal polycythemia and hyperviscosity; state of the art</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neonatal polycythemia and hyperviscosity; state of the art</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819947" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hemodynamic consequences of neonatal polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7267222" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Neonatal polycythemia: I. Criteria for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7263331" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hyperviscosity secondary to polycythemia in the appropriate for gestational age neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7119965" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Estimated blood volumes in polycythemic neonates as a function of birth weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23843134" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4702893" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hyperviscosity in the neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/450517" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neonatal hyperviscosity: I. Incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1756079" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cord whole blood hyperviscosity: measurement, definition, incidence and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691031" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Neonatal polycythemia: II. Definition related to time of sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3585609" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Postnatal alteration in hematocrit and viscosity in normal and polycythemic infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10856980" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rheological influences on thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24030677" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Whole-blood viscosity in the neonate: effects of gestational age, hematocrit, mean corpuscular volume and umbilical cord milking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9181760" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neonatal whole blood hyperviscosity: the important factor influencing later neurologic function is the viscosity and not the polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6694026" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cerebral blood flow in the newborn lamb with polycythemia and hyperviscosity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6694026" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cerebral blood flow in the newborn lamb with polycythemia and hyperviscosity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660438" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Early cord clamping protects at-risk neonates from polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12869126" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Circulating RBC volume, measured with biotinylated RBCs, is superior to the Hct to document the hematologic effects of delayed versus immediate umbilical cord clamping in preterm neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13770150" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Maternal-fetal transfusion as a cause of plethora in the neonatal period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13645107" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Congenital adrenal hyperplasia associated with polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3631000" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Polycythemia in hypothyroid infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/830919" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neonatal thyrotoxicosis associated with the hyperviscosity syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/657602" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Polycythaemia and the hyperviscosity syndrome in newborn infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4000778" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Neonatal hyperviscosity: randomized study of effect of partial plasma exchange transfusion on long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6175948" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Developmental and neurologic sequelae of neonatal hyperviscosity syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3601521" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Partial exchange transfusion in term, polycythemic neonates: absence of association with severe gastrointestinal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7460803" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The management of polycythaemia in the newborn infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6175947" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neonatal hyperviscosity. II. Effect of partial plasma exchange transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7086629" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Normal coagulation findings, thrombocytopenia, and peripheral hemoconcentration in neonatal polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7086629" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Normal coagulation findings, thrombocytopenia, and peripheral hemoconcentration in neonatal polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7133792" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Neonatal polycythemia and hyperviscosity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552399" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Asymptomatic syndrome of polycythemic hyperviscosity: effect of partial plasma exchange transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2769507" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diagnostic errors in neonatal polycythemia based on method of hematocrit determination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20725868" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Management of polycythemia in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15325537" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Neonatal polycythemia: is partial exchange transfusion justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21457305" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Neonatal polycythaemia: critical review and a consensus statement of the Israeli Neonatology Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10986862" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Thrombocytopenia: an important indicator for the application of partial exchange transfusion in polycythemic newborn infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123865" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of partial exchange transfusion in asymptomatic polycythemic LBW babies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7086628" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cerebral blood flow velocity in infants with polycythemia and hyperviscosity: effects of partial exchange transfusion with Plasmanate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3953635" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Partial plasma exchange transfusion improves cerebral hemodynamics in symptomatic neonatal polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2792132" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of partial plasma exchange transfusion on cerebral blood flow velocity in polycythaemic preterm, term and small for date newborn infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21595746" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Partial exchange transfusion results in increased cerebral oxygenation and faster peripheral microcirculation in newborns with polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4069859" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effects of neonatal polycythemia and partial exchange transfusion on cardiac function: an echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2717281" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Neonatal hyperviscosity association with lower achievement and IQ scores at school age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174666" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Short and long term outcomes following partial exchange transfusion in the polycythaemic newborn: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091569" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Partial exchange transfusion to prevent neurodevelopmental disability in infants with polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371393" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Systematic review of the optimal fluid for dilutional exchange transfusion in neonatal polycythaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303705" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Crystalloid or colloid for partial exchange transfusion in neonatal polycythemia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4022696" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Gastrointestinal injury in polycythemic term infants.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
